Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology
October 25, 2021 11:35 ET
|
Todos Medical Ltd.
New York, NY, and Tel Aviv, ISRAEL, Oct. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related...
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
October 21, 2021 10:18 ET
|
Todos Medical Ltd.
Company hosting cPass webinar on Friday, October 22, 2021 for long-term care facilities New York, NY, and Tel Aviv, ISRAEL, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos...
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT
October 14, 2021 12:30 ET
|
Todos Medical Ltd.
Dr. Jorge Leone, Chief Scientific Officer of Todos Medical, and Sean Taylor, North American FAS Manager of Genscript, will discuss the importance of the cPass™ SARS-COV-2 neutralizing antibody...
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay
October 06, 2021 11:00 ET
|
Todos Medical Ltd.
Data demonstrated very high correlation with PCR ct values in positive patients Data demonstrated 100% sensitivity, as early as 1-3 days post-exposure, in identifying fully vaccinated asymptomatic...
UPDATE - Todos Medical Announces October Conference Calendar
October 05, 2021 06:00 ET
|
Todos Medical Ltd.
NEW YORK, NY and Tel Aviv, ISRAEL, Oct. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related...
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck
October 04, 2021 07:30 ET
|
Todos Medical Ltd.
New York, NY, and Tel Aviv, ISRAEL, Oct. 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related...
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir®
September 30, 2021 09:08 ET
|
Todos Medical Ltd.
- Treatment group participants experienced a reduction in key inflammatory biomarker - Observed a reduction in time of hospitalization and death rate with no deaths recorded in...
Todos Medical Announces October Conference Calendar
September 28, 2021 09:09 ET
|
Todos Medical Ltd.
New York, NY, and Tel Aviv, ISRAEL, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related...
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™
September 27, 2021 07:30 ET
|
Todos Medical Ltd.
Tollovid® and Tollovid Daily™ are now available for immediate purchase on Amazon.com New York, NY, and Tel Aviv, ISRAEL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd....
Todos Medical Reports Second Quarter 2021 Financial Results
September 24, 2021 09:36 ET
|
Todos Medical Ltd.
Company recorded positive earnings of $0.01 per share as financial condition improved New York, NY, and Tel Aviv, ISRAEL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical,...